CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Epizyme Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Epizyme Inc
400 Technology Square, 4Th Floor
Phone: (617) 229-5872p:617 229-5872 CAMBRIDGE, MA  02139-3584  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 8/12/2022.
This company ceased filing statements with the SEC on 8/23/2022.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Epizyme, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the treatment of people with cancer through the discovery, development, and commercialization of epigenetic medicines. The Company's lead product TAZVERIK (tazemetostat) is used for epithelioid sarcoma (ES), and follicular lymphoma (FL). Tazemetostat is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase (HMT), for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced ES not eligible for complete resection. It is developing tazemetostat for lymphomas and B-cell malignancies, including B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), multiple myeloma and others. Its advanced product candidate, EZM0414, is an oral inhibitor of the SETD2 HMT. The Company is assessing the use of tazemetostat for immuno-oncology-sensitive tumors, such as small cell lung cancer, prostate cancer, and others.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board David M.Mott 56 4/1/2016 12/1/2009
President, Chief Executive Officer, Director Grant C.Bogle 64 8/9/2021 9/2/2019
Chief Operating Officer JeraldKorn 42 3/21/2022 3/21/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Epizyme Securities Corporation
EpiZyme, Inc.
EPZM

General Information
Number of Employees: 250 (As of 3/1/2022)
Outstanding Shares: 168,364,752 (As of 8/5/2022)
Shareholders: 12
Stock Exchange: NASD
Federal Tax Id: 261349956
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 5, 2024